home / stock / bcda / bcda news

BCDA News and Press, BioCardia Inc. From 03/27/24

Stock Information
Company Name: BioCardia Inc.
Stock Symbol: BCDA
Market: OTC
Website: biocardia.com
Menu
BCDA BCDA Quote BCDA Short BCDA News BCDA Articles BCDA Message Board
Get BCDA Alerts

News, Short Squeeze, Breakout and More Instantly...
BCDA - Expected US Company Earnings on Wednesday, March 27th, 2024

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
BCDA - BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 3...

BCDA - BioCardia and StemCardia partners for heart failure treatment candidate

2024-03-13 08:36:14 ET More on BioCardia BioCardia spikes after Medicare coverage for cell therapy trial Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia Financial information for BioCardia Read the full articl...

BCDA - BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Partnership targets heart failure, the leading cause of death and a condition with limited treatment options BioCardia’s biotherapeutic delivery system with established safety profile enables minimally invasive transplantation of StemCardia’s off-the-shelf cardiac muscle cel...
BCDA - BioCardia spikes after Medicare coverage for cell therapy trial

2024-03-12 08:58:54 ET More on BioCardia Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia Financial information for BioCardia Read the full article on Seeking Alpha For further details see: BioCardia spikes a...

BCDA - BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

SUNNYVALE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement...

BCDA - BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at mean 20-month follow-up c...
BCDA - BioCardia to sell 3.02M shares for holders

2024-02-14 17:10:43 ET More on BioCardia Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia Financial information for BioCardia Read the full article on Seeking Alpha For further details see: BioCardia to sell ...

BCDA - BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chron...

BCDA - BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

SUNNYVALE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chron...
Previous 10 Next 10